AlphAIalphai — Financial news for AI agents
SEC EDGARMAY 271 min read$BDX

Feld Michael sold $11K of BDX

Feld Michael (EVP, Chief Revenue Officer) sold 75 shares of BECTON DICKINSON & CO (BDX) at $147.35 on 2026-05-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Feld Michael
Published May 27, 2026, 5:41 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 5:46 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BDX
Neutral
high confidence
Mentioned
$BDX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BDXNeutralLow
01

Why it matters

Routine 10b5-1 selling typically has limited informational content; traders may treat it as low-signal unless paired with other negative catalysts.

02

Market read

A small, planned insider sale is unlikely to materially change valuation expectations for BDX absent other news.

03

What to watch

Consider whether there were multiple recent insider transactions or changes in trading patterns; this single small sale is not enough to infer trend.

Relevance 6/10Timing: Immediate (filed 2026-05-27) but event is routine insider selling.

Background

The article is an SEC Form 4 insider transaction disclosure for Becton Dickinson (BDX).

Company-level read

Ticker impact

$BDXNeutralHigh confidence
Context

BDX EVP/Chief Revenue Officer Michael Feld sold 75 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any move would more likely be noise around routine insider activity.

Evidence & confidence

Form 4 shows a small, pre-planned open-market sale (75 shares) rather than a discretionary trade tied to new fundamentals.

Market effects

Sector

No clear read-through to medical devices demand or competitive dynamics from a small, planned insider sale.

Regional

None indicated; filing is US-based and company-specific.

Global

None indicated; transaction does not reference global operations or guidance changes.

Counterpoint

What could challenge this read

Insider selling can still reflect personal liquidity needs; however, the 10b5-1 designation reduces the probability of an information-driven signal.

Key entities

  • insider
    Michael Feld

    EVP, Chief Revenue Officer at Becton Dickinson; sold 75 shares on 2026-05-26 under a pre-arranged 10b5-1 plan.

  • issuer
    Becton Dickinson & Co

    Issuer of the reported insider transaction; shares sold at $147.35 each, total value $11,051.25.

Read at source← All news

Related articles

AUG 8
$REPLMed

This Week at FDA: Inspection reorg, acting CBER chief eyes IND reforms, and more

FDA updates cover inspection reorganization plans, proposed IND reforms for early-stage biologics research, and accelerated approval of Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg) with Bristol Myers Squibb’s Opdivo for melanoma after PD-1 regimens. Other items include FDA workshops, Seegene EUA for an assay, and multiple drug/device recalls.

raps.org7 min
AUG 6
$BDXMed

Becton, Dickinson Boosts FY26 Adj. EPS Outlook - Update

Becton, Dickinson and Co. (BDX) reported third-quarter results and raised its FY2026 adjusted EPS outlook to $12.62 to $12.72 per share, from $12.52 to $12.72. The company kept its revenue growth view, expecting low single-digit plus growth and low single-digit constant-currency growth. Shares were about $172.00 premarket.

rttnews.com2 min
AUG 6
$BDXMedAI 8/10

BD Reports Third Quarter Fiscal 2026 Financial Results

BD (NYSE:BDX) reported fiscal 2026 third-quarter results ended June 30, 2026. Revenue rose to $5.0 billion, up 5.4% reported and 4.4% on an FX-neutral basis. GAAP and adjusted diluted EPS from continuing operations were $1.64 and $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion, and free cash flow rose 44.6% to $1.7 billion. BD updated full-year guidance, expecting revenue growth toward the high end and raised the adjusted EPS midpoint.

prnewswire.com6 min